AU2021239957A1 - Boronic acid derivatives and therapeutic uses thereof - Google Patents
Boronic acid derivatives and therapeutic uses thereof Download PDFInfo
- Publication number
- AU2021239957A1 AU2021239957A1 AU2021239957A AU2021239957A AU2021239957A1 AU 2021239957 A1 AU2021239957 A1 AU 2021239957A1 AU 2021239957 A AU2021239957 A AU 2021239957A AU 2021239957 A AU2021239957 A AU 2021239957A AU 2021239957 A1 AU2021239957 A1 AU 2021239957A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- crystalline form
- crystallization solution
- heated
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991496P | 2020-03-18 | 2020-03-18 | |
| US62/991,496 | 2020-03-18 | ||
| PCT/US2021/022799 WO2021188700A1 (en) | 2020-03-18 | 2021-03-17 | Boronic acid derivatives and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021239957A1 true AU2021239957A1 (en) | 2022-10-13 |
Family
ID=77771374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021239957A Pending AU2021239957A1 (en) | 2020-03-18 | 2021-03-17 | Boronic acid derivatives and therapeutic uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230151029A1 (https=) |
| EP (1) | EP4121433A4 (https=) |
| JP (1) | JP7819925B2 (https=) |
| KR (1) | KR20220156047A (https=) |
| CN (1) | CN116034109A (https=) |
| AU (1) | AU2021239957A1 (https=) |
| BR (1) | BR112022018586A2 (https=) |
| CA (1) | CA3176060A1 (https=) |
| IL (1) | IL296515A (https=) |
| MX (1) | MX2022011565A (https=) |
| TW (1) | TW202200157A (https=) |
| WO (1) | WO2021188700A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2894251T3 (es) | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
| BR112022022367A2 (pt) | 2020-05-05 | 2023-01-10 | Qpex Biopharma Inc | Derivados e síntese de ácido borônico, formas polimórficas e usos terapêuticos dos mesmos |
| WO2023066292A1 (zh) * | 2021-10-19 | 2023-04-27 | 上海济煜医药科技有限公司 | 三环类硼酸衍生物及其制备方法和应用 |
| KR102902654B1 (ko) | 2024-03-27 | 2025-12-22 | 영남대학교 산학협력단 | 페닐보론산 유도체 화합물을 유효성분으로 포함하는 비브리오균의 바이오필름 형성 억제용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015179308A1 (en) * | 2014-05-19 | 2015-11-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| ES2894251T3 (es) | 2016-06-30 | 2022-02-14 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos |
| MX2020003495A (es) * | 2017-10-11 | 2020-09-18 | Qpex Biopharma Inc | Derivados de acido boronico y sintesis de los mismos. |
-
2021
- 2021-03-17 WO PCT/US2021/022799 patent/WO2021188700A1/en not_active Ceased
- 2021-03-17 EP EP21772502.7A patent/EP4121433A4/en active Pending
- 2021-03-17 BR BR112022018586A patent/BR112022018586A2/pt unknown
- 2021-03-17 MX MX2022011565A patent/MX2022011565A/es unknown
- 2021-03-17 TW TW110109612A patent/TW202200157A/zh unknown
- 2021-03-17 CA CA3176060A patent/CA3176060A1/en active Pending
- 2021-03-17 IL IL296515A patent/IL296515A/en unknown
- 2021-03-17 JP JP2022556042A patent/JP7819925B2/ja active Active
- 2021-03-17 KR KR1020227036094A patent/KR20220156047A/ko active Pending
- 2021-03-17 AU AU2021239957A patent/AU2021239957A1/en active Pending
- 2021-03-17 CN CN202180035963.3A patent/CN116034109A/zh active Pending
- 2021-03-17 US US17/906,340 patent/US20230151029A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023518418A (ja) | 2023-05-01 |
| CN116034109A (zh) | 2023-04-28 |
| IL296515A (en) | 2022-11-01 |
| MX2022011565A (es) | 2023-02-27 |
| EP4121433A4 (en) | 2024-06-19 |
| WO2021188700A1 (en) | 2021-09-23 |
| CA3176060A1 (en) | 2021-09-23 |
| JP7819925B2 (ja) | 2026-02-25 |
| BR112022018586A2 (pt) | 2022-12-20 |
| US20230151029A1 (en) | 2023-05-18 |
| KR20220156047A (ko) | 2022-11-24 |
| TW202200157A (zh) | 2022-01-01 |
| EP4121433A1 (en) | 2023-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3139930B1 (en) | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof | |
| US12171772B2 (en) | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | |
| JP7819925B2 (ja) | ボロン酸誘導体およびその治療的使用 | |
| US9241947B2 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| CA2982911C (en) | Methods of treating bacterial infections | |
| US9120795B2 (en) | Crystalline form of a β-lactamase inhibitor | |
| EP3986419B1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| HK40093370A (zh) | 硼酸衍生物及其治疗用途 | |
| HK40072316A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| HK40032404B (en) | Cyclic boronic acid ester derivatives and therapeutic uses thereof |